RecruitingNCT05234177

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays

Sponsor

Tempus AI

Enrollment

300 participants

Start Date

Jun 21, 2022

Study Type

OBSERVATIONAL

Conditions

Colorectal, Cancer

Summary

The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tracks patients with colorectal cancer (colon or rectal cancer) to see if a blood test that detects tiny fragments of cancer DNA — called circulating tumor DNA (ctDNA) — can help doctors catch cancer coming back earlier. Blood samples are collected at routine follow-up visits. **You may be eligible if...** - You have been diagnosed with colorectal cancer (stage I through IVA) - You have had or are planning to have surgery to remove the cancer - You are 18 years old or older - You are willing to have extra blood samples drawn during regular check-up visits **You may NOT be eligible if...** - You are not willing to provide blood samples - Your cancer type is not colorectal adenocarcinoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation

No intervention

Locations(20)

Mercy Clinic Oncology - Fort Smith

Fort Smith, Arkansas, United States

MemorialCare

Fountain Valley, California, United States

The Center for Cancer and Blood Disorders

Bethesda, Maryland, United States

Mercy Clinic Oncology and Hematology - Joplin

Joplin, Missouri, United States

Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center

Springfield, Missouri, United States

Washington University School of Medicine

St Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - Sindelar Cancer Center

St Louis, Missouri, United States

Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center

St Louis, Missouri, United States

Nebraska Cancer Specialists

Omaha, Nebraska, United States

Southeastern Medical Oncology Center

Goldsboro, North Carolina, United States

Aultman Hospital

Canton, Ohio, United States

TriHealth Cancer Institute

Cincinnati, Ohio, United States

Ohio State University

Columbus, Ohio, United States

OhioHealth Research Institute

Columbus, Ohio, United States

Toledo Clinic Cancer Center

Toledo, Ohio, United States

Mercy Clinic Oncology and Hematology - Coletta

Oklahoma City, Oklahoma, United States

Cancer Care Associates of York

York, Pennsylvania, United States

Utah Cancer Specialists

Salt Lake City, Utah, United States

University of Washington / Fred Hutchinson Cancer Center

Seattle, Washington, United States

ThedaCare Regional Cancer Center

Appleton, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05234177

Related Trials

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

NCT072192382 locations

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

NCT072616318 locations

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT048999082 locations

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT0578692427 locations

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT0548921196 locations